BioPharma Resources

Drug Trial Radar · NCT06627751

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

May 1, 2027

Study completion May 1, 2030

Sponsor

Lead sponsor
Roswell Park Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \[EMD\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed/refractory multiple myeloma (RRMM) with EMD.

Conditions

  • Extramedullary Disease in Multiple Myeloma
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma

Interventions

  • MezigdomideBiological

    Given PO

  • CarfilzomibDrug

    Given IV

  • DexamethasoneDrug

    Given PO

  • EchocardiographyProcedure

    Undergo ECHO

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Computed TomographyProcedure

    Undergo PET/CT

  • Computed Tomography Assisted BiopsyProcedure

    Undergo CT guided tumor Biopsy

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration biopsy

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Biospecimen CollectionProcedure

    Undergo blood and saliva sample collection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: At the end of cycle 6 (each cycle is 28 days).
  2. Clinical benefit rateTime frame: At the end of cycle 6 (each cycle is 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.